ClinicalTrials.gg
RecruitingNCT06707012Updated Sep 19, 2025

Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients

A Phase 4 interventional study of Metformin Hydrochloride in Depression, sponsored by Fazaia Ruth Pfau Medical College. Recruiting at 2 sites in Pakistan. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Fazaia Ruth Pfau Medical College · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing metformin in Depression — 3 open to participants now, 3 under way, none of them phase 3. Metformin · Depression.

Planned enrollment
3rd of 10
140 · median 71
Started
2025
the only one that year
Phase 4
6 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Fazaia Ruth Pfau Medical College

Among the 10 studies testing metformin in Depression, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 4, and was the 8th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

3 of the 10 studies testing metformin in Depression are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing metformin in Depression, or all of them as a file.
02

Study summary

To evaluate the efficacy of metformin as an adjunct therapy in improving depressive symptoms and metabolic markers in newly diagnosed obese depressed patients on standard antidepressant therapy.

investigator will compare between Two groups

1. metformin group 2 placebo group Primary outcome measure will be the improvement in depressive symptoms, indicating by a reduction in Hamilton Depression Rating Scale (HAM-D) scores. Secondary outcome measures will include the assessment of oxidative stress markers, specifically by measuring the increase in enzymatic activity of superoxide dismutase, catalase, and glutathione peroxidase Investigators hypothesize that the addition of metformin to standard antidepressant treatment will result in a significant reduction in symptoms of depression among newly diagnosed obese individuals.

Read the detailed description

This is a comparative clinical study with randomized groups. Participants will be allocated to either the metformin group or the placebo group in conjunction with standard antidepressant therapy. Randomization will be achieved using computer generated numbers in 1:1 ratio.

Metformin Group: Starting dose of 500 mg metformin once daily, titrated up to 2000 mg/day based on tolerance along with standard treatment of depression according to Maudsley guidelines.

Placebo Group: Identical placebo tablets, following the same titration schedule as the metformin group along with standard treatment of depression.

Study will take place at psychiatric Out Patient Department of Fazaia Ruth Pfau Medical College and Hospital Karachi Pakistan

Investigators will recruit participants from the psychiatric outpatient department of PAF Hospital diagnosed with depression according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition for at least 2 weeks and having obesity. depression is assessed with help of Hamilton Depression Scale (HAM-D). Participants whose score is above 8 and will meet the inclusion criteria will be added in study.

Informed consent:

Participants who meets the criteria will be asked for written informed consent form and explain in detail about the study

Base Line Data Collection After taking informed consent, detailed history, physical examination, HbA1c and serum creatinine will be measured. Participants whose HbA1c results is below 5.7% and creatinine clearance is above 30% will be selected in the study. Investigators will assess HbA1c, serum creatinine levels at every 12 weeks' interval. Serum levels of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) will measured in participants by using biochemical assays at baseline and at the end of the study.

Follow up visits Participants will be followed up six times throughout the study duration. 1st follow up visit will occur at 4th week to evaluate the response to treatment by using Hamilton depression rating scale for depression, as according to Maudsley guidelines initial response to treatment should be assessed within 4 weeks. Next follow ups will take place at every 6th week till 36 weeks to assess improvement in depression and changes in BMI.

03

Conditions studied

  • Depression

Keywords

  • Depression
  • oxidative stress
  • antidepressants
  • obesity
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age >18 to \<45 years

      • Gender: Both genders (Male and Female)
      • >25
      • Diagnosis: Newly diagnose cases of depression (mild to severe)
      • : Less than 5.7% (non-diabetic range)

Exclusion criteria

Exclusion Criteria:

  • Existing diabetes

    • Acute illnesses like acute kidney injury, recent history of myocardial infarction, acute liver injury
    • Intellectual disabilities or inability to understand due to any reason
    • Presence of Psychiatric disorders other than depression
    • Chronic kidney disease ( \< 45 mL/min/1.73 m²).
    • Use of any psychotropic medication within the past 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Experimental

    We will prescribe metformin with starting dose of 500 mg metformin once daily, titrated up to 2000 mg/day based on tolerance along with standard treatment of depression according to Maudsley guidelines.

    Drug: Metformin Hydrochloride

  • Placebo comparator
    placebo group

    Identical placebo tablets, following the same titration schedule as the metformin group along with standard treatment of depression

    Drug: Metformin Hydrochloride

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be divided in 2 groups 1 group will receive metformin and 2nd group will receive placebo

    Also known as: GLUCOPHAGE

06

What researchers measure

Primary outcomes

  1. Decrease scoring of Hamilton depression rating scale

    Primary outcome measure will be the improvement in depressive symptoms, indicating by a change in Hamilton Depression Rating Scale (HAM-D) scores. Decrease in the score will be considered as indicator of improvement in depression. 0-7: Normal (no depression) 8-13: Mild depression 14-18: Moderate depression 19-22: Severe depression 23 and above: Very severe depression Investigators will compare the change in both groups.

    Time frame: 18 months

Secondary outcomes

  1. elevation in oxidative enzymes level (superoxide dismutase,catalase,glutathione peroxidase

    Secondary outcome measures will include the change in oxidative stress markers, specifically by measuring the enzymatic activity of superoxide dismutase, catalase, and glutathione peroxidase. Increase in levels of enzymes will be considered as indicator of improvement of depression. investigators will compare the change in both groups.

    Time frame: 18 months

Other outcomes

  1. change in Basal Metabolic Rate

    weight in kilograms and height in meters of the participants will be assessed at each follow up visit to identify change in basal metabolic rate and will compare between groups

    Time frame: 18 months

07

Study locations

2 of 2 sites recruiting
  • Fazaia Rurh Pfau Medical College
    Karachi, Sindh 75120, Pakistan
    Recruiting
    • Masood Ahmed, MBBS,PHD · Contactprincipal.frpmc@mail.au.edu.pk · 03002922361
    • Asgher Mehdi, MBBS · Contactdrasgharmehdi@gmail.com · 03008228284
    • sadia khan, MBBS · Principal investigator
    • Asghar Mehdi, MBBS,PHD · Sub investigator
    • Tooba Riaz, MBBS · Sub investigator
    • Asad Afridi, MBBS,PHD · Sub investigator
    • Natasha Billia, MBBS,PHD · Sub investigator
  • Fazaia Ruth Pfau Medical College
    Karachi, Sindh 75120, Pakistan
    Recruiting
08

References and documents

Publications

  • Guo M, Mi J, Jiang QM, Xu JM, Tang YY, Tian G, Wang B. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 2014 Sep;41(9):650-6. doi: 10.1111/1440-1681.12265. PubMed 24862430 ↗
  • Farooq S, Khan T, Zaheer S, Shafique K. Prevalence of anxiety and depressive symptoms and their association with multimorbidity and demographic factors: a community-based, cross-sectional survey in Karachi, Pakistan. BMJ Open. 2019 Nov 19;9(11):e029315. doi: 10.1136/bmjopen-2019-029315. PubMed 31748286 ↗
  • Heiskanen TH, Niskanen LK, Hintikka JJ, Koivumaa-Honkanen HT, Honkalampi KM, Haatainen KM, Viinamaki HT. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry. 2006 Sep;67(9):1422-7. doi: 10.4088/jcp.v67n0913. PubMed 17017829 ↗
  • Lang UE, Beglinger C, Schweinfurth N, Walter M, Borgwardt S. Nutritional aspects of depression. Cell Physiol Biochem. 2015;37(3):1029-43. doi: 10.1159/000430229. Epub 2015 Sep 25. PubMed 26402520 ↗
  • Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010 Mar;67(3):220-9. doi: 10.1001/archgenpsychiatry.2010.2. PubMed 20194822 ↗
  • Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47-53. doi: 10.1002/j.1550-8528.1998.tb00314.x. PubMed 9526970 ↗
  • Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):27-31. doi: 10.1055/s-0032-1327734. Epub 2012 Nov 12. PubMed 23147210 ↗
  • AlHussain F, AlRuthia Y, Al-Mandeel H, Bellahwal A, Alharbi F, Almogbel Y, Awwad O, Dala'een R, Alharbi FA. Metformin Improves the Depression Symptoms of Women with Polycystic Ovary Syndrome in a Lifestyle Modification Program. Patient Prefer Adherence. 2020 Apr 15;14:737-746. doi: 10.2147/PPA.S244273. eCollection 2020. PubMed 32346286 ↗
  • Calkin CV, Chengappa KNR, Cairns K, Cookey J, Gannon J, Alda M, O'Donovan C, Reardon C, Sanches M, Ruzickova M. Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the TRIO-BD Study): A Randomized, Quadruple-Masked, Placebo-Controlled Clinical Trial. J Clin Psychiatry. 2022 Feb 1;83(2):21m14022. doi: 10.4088/JCP.21m14022. PubMed 35120288 ↗
  • Jitca G, Gall Z, Jitca CM, But MG, Majai E. Drug Repurposing of Metformin for the Treatment of Haloperidol-Related Behavior Disorders and Oxidative Stress: A Preliminary Study. Pharmaceutics. 2024 Mar 15;16(3):403. doi: 10.3390/pharmaceutics16030403. PubMed 38543297 ↗

Individual participant data

Plan to share: No — It will be shared if required by authority

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jun 2026, 8 months later.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 8 months is below that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2024
First posted
Nov 27, 2024
StartEst.
Oct 1, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06707012
Lead sponsor
Fazaia Ruth Pfau Medical College
Responsible party
Sadia khan (Dr. Sadia Khan MBBS resident FCPS Pharmacology, Fazaia Ruth Pfau Medical College) — Principal investigator
First posted
Nov 27, 2024
Start date
Oct 1, 2025 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 19, 2025

Study contacts

Sadia khan, MBBS
Contact
sadiakhansk30@gmail.com
0331359046 ext. 314
Asghar Mehdi, MBBS,PHD
Contact
drasgharmehdi@gmail.com
03008228284 ext. 316
sadia khan, MBBS
principal investigator · Fazaia Ruth Pfau Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion